AC Immune Ltd (ACIU)

AC Immune Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing medicines, as well as therapeutic and diagnostic products, for neurodegenerative diseases linked to protein misfolding. Its research programs are built around the SupraAntigen and Morphomer platforms, which are intended to produce biologics and small molecules that bind selectively to misfolded proteins associated with these disorders. The company’s pipeline includes Crenezumab for Alzheimer’s disease, Semorinemab for Alzheimer’s disease, ACI-24.060 for Down syndrome-related Alzheimer’s disease, ACI-7104.056 for Parkinson’s disease, and ACI-35.030, which is designed to stimulate an immune response against pathological phosphorylated Tau. AC Immune is also developing diagnostic candidates such as PI-2620, ACI-12589, and ACI-15916, alongside additional discovery and preclinical programs targeting neurodegenerative disease biology. The company has collaboration and license agreements with Genentech, Janssen Pharmaceuticals, Life Molecular Imaging, and Eli Lilly. Founded in 2003, AC Immune is headquartered in Lausanne, Switzerland.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.